Loading…
for educational and safety purposes
class, effects, and the receptor fingerprint, side by side; add up to four, then source the whole stack
Popular head-to-heads →AMPA receptorspositive modulator
Acetylcholine releaseincreases
Phospholipid metabolismboosts
Dopamine (prefrontal)facilitates
Broad CNS receptor safety panel (19 targets, including NMDA GRIN1, GABA-A alpha1, muscarinic M1 and M3, nicotinic alpha4, D2, 5-HT2C, adenosine A1 and A3, mu- and kappa-opioid, alpha1A/alpha2B/beta1-adrenergic, H1, DAT, NET, hERG, ENT1)No measurable activity; this is a negative result and the best-supported target fact about the compound
AMPA-type ionotropic glutamate receptorPositive modulation (functional; increases agonist efficacy, not potency)
Cortical and hippocampal cholinergic transmission (acetylcholine utilisation, high-affinity choline uptake)Indirect presynaptic enhancement
NMDA receptor, glycine co-agonist site (functional)Reversal of kynurenic acid antagonism
Protein kinase C (membrane translocation and activation)Transient activator followed by down-regulation
Depolarisation-evoked excitatory amino acid release (hippocampus)Biphasic enhancement, with an inverted-U concentration response
alpha7 nicotinic acetylcholine receptor / PI3K-Akt signallingUpregulation (enantiomer-specific, indirect, protein-expression level)
Choline transporter CHT1 (HACU)enhances
Cerebral blood flowraises
AMPA glutamatemodulates
Sodium-dependent high-affinity choline uptake (hippocampus and cortex)Increases choline uptake; bell-shaped dose-response
Classical neurotransmitter receptors (adrenergic alpha1/alpha2/beta, muscarinic, 5-HT, dopamine, adenosine A1, mu-opioid, GABA, benzodiazepine, glutamate)No measurable affinity
Choline transport across the blood-brain barrierNormalises scopolamine-induced changes in choline permeability; increases cerebral blood flow
Neuronal nitric oxide synthase (nNOS)Increases enzyme activity without changing NOS mRNA
Prolyl endopeptidase (prolyl oligopeptidase)Inhibitor
Adrenal steroid / aldosterone (mineralocorticoid) receptor pathwayPermissive requirement, not a direct target; memory effect is abolished without intact steroid signalling
Thromboxane A2 pathway (platelet aggregation)Antiaggregant, reported as mediated mainly via inhibition of thromboxane A2 metabolism
checking Oxiracetam and Pramiracetam: no notable interaction flagged; they read as broadly independent.
no notable interaction flagged; these look broadly independent.
General educational info, not medical advice.
The vendors that carry the most of your 2 picks; fewer vendors, fewer codes, less shipping.